Simply head over to the account section in settings and click on “Cancel Subscription” - it’s as simple as that. After you cancel, your membership will stay active for the remainder of the time you’ve paid for. Learn more here.

At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.

Both plans give you full access to the library and all of Perlego’s features. The only differences are the price and subscription period: With the annual plan you’ll save around 30% compared to 12 months on the monthly plan.

We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.

Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.

Yes, you can access New Aspects in Diabetes by Pierre J. Lefèbvre, Eberhard Standl, Pierre J. Lefèbvre, Eberhard Standl in PDF and/or ePUB format, as well as other popular books in Medicine & Medical Theory, Practice & Reference. We have over one million books available in our catalogue for you to explore.

Information

Publisher

De Gruyter

Year

2019

ISBN

9783110859447

Edition

Topic

Medicine

Subtopic

Medical Theory, Practice & Reference

List of first-mentioned contributors
Contents
Introduction
I. New aspects in diabetes mellitus
The epidemiology of diabetes mellitus and its relationship with cardiovascular disease
Syndrome X: fact or fiction?
Strategies for the treatment of hyperglycemia in Syndrome X
Treatment strategies of Syndrome X — hypertension and vascular complications
Lipid metabolism: metabolic consequences of moderate hypertriglyceridemia
Update on the treatment of NIDDM
Hyperinsulinemia and macrovascular complications in NIDDM
II. Quality of life in diabetes mellitus
Diabetes and quality of life: some current issues in definition and research
Quality of life in patients with type II diabetes mellitus
Well-being in non-insulin-dependent diabetic patients (NIDDM) - a long-term follow-up
III. Studies with acarbose
Acarbose monotherapy in non-insulin-dependent diabetes mellitus — the German experience
Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet
Clinical efficacy of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus (NIDDM) — a placebo-controlled double-blind comparative study
Effects of long-term administration of acarbose in patients with NIDDM - a double-blind study with placebo
Effects of acarbose on blood glucose control in insulindependent diabetes mellitus
European experience in the treatment of IDDM with acarbose in combination with insulin
Round table discussion on open questions and future aspects
IV. Abstracts
A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone
A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) and sulfonylureas in the treatment of NIDDM inadequately controlled by maximal doses of sulfonylureas (SFU)
A multi-center, double-blind, comparative study of the long-term efficacy and safety of acarbose (BAY g 5421) vs. placebo in the treatment of patients with insulin requiring type II diabetes mellitus
Prospective, multi-center studies of the efficacy and safety of acarbose (BAY g 5421) in the treatment of type I diabetes mellitus
Two multi-center, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes
Clinical study of reduced postprandial hyperglycemia by acarbose and glycemic impact of fructose and sucrose in insulin therapy
6 months monotherapy of NIDDM with acarbose or glibenclamide
Decreased insulin requirement and postprandial insulin plasma concentrations under treatment with the a-glucosidase inhibitor acarbose
Long-term treatment of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus
Clinical efficacy and tolerability of acarbose in IDDM treatment
Effects of acarbose on the glycemic index of different foods
Effects of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in type II diabetics
Influence of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in healthy volunteers
Acarbose: an intestinal tract a-glucosidase inhibitor — pharmacological effects on insulin and glycemia in response to a sucrose load
Assessment of efficacy and tolerability of acarbose (Glucobay<sup>®</sup>) by clinical data pool
Long-term tolerability of acarbose
Assessment of efficacy and tolerability of acarbose in diabetic patients 5 — 16 years of age
Effect of acarbose repeated dosing on antipyrine test in healthy volunteers
Discussion